Israeli telehealth startup Antidote Health, raised $22 million in Series A funding to accelerate its R&D activities and broaden its affordable healthcare services nationwide within the United States, the company announced this week.
The round was led by existing investors, iAngels, Group 11, and Flint Capital.
“This Series A funding round will allow Antidote Health to help Americans in more ways than ever by adding chronic and primary care services that are backed by our innovative technology and amazing care teams,” says Avihai Sodri, co-founder and CEO of Antidote Health. “We’re extremely thankful that our investors believe in our purpose of providing affordable quality healthcare for all.”
Founded in 2020, Antidote Health developed a telehealth platform that leverages AI and machine learning to deliver premium, acute, and chronic care health services at a dramatically reduced price compared to other healthcare services. Its technology streamlines patient screening and is compatible with businesses of any size, non-profits, families, and individuals. Currently, Antidote Health’s platform is available to roughly 60 percent of the US population.
In October, Antidote Health was one of 10 startups selected to join the 5th cohort of Google’s Startup Growth Lab.
“We’re thrilled to invest in Antidote Health, as it caters to a fundamental problem in the $4 trillion healthcare market that can only be solved through the development and implementation of cutting-edge technology. said Shelly Hod Moyal, founding partner at iAngels. Leveraging a scalable AI-platform powered by 20 years of clinical data, the team is experiencing exceptional growth and lucrative unit economics as it breaks into this untapped opportunity.”
“The US healthcare market is laden with billions of dollars of operational and administrative inefficiencies, leading to unaffordable and inaccessible healthcare for millions of Americans. said Dovi Frances, founding partner at Group 11. “We believe Antidote’s AI-driven, digital-first approach can increase accessibility to excellent patient care, and their fully embedded financial product layer can improve affordability of services. Their value proposition to the uninsured population is a true blue ocean discovery.”